• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form S-8 POS filed by Assertio Holdings Inc.

    6/16/26 4:58:41 PM ET
    $ASRT
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $ASRT alert in real time by email
    S-8 POS 1 tm2617901d17_s8pos.htm S-8 POS

     

    As filed with the Securities and Exchange Commission on June 16, 2026

     

    Registration No. 333-287395

    Registration No. 333-279772

    Registration No. 333-271947

    Registration No. 333-264880

    Registration No. 333-238926

    Registration No. 333-238925

    Registration No. 333-231366

    Registration No. 333-228290

    Registration No. 333-224924

    Registration No. 333-211643

    Registration No. 333-211642

    Registration No. 333-196263

    Registration No. 333-181710

    Registration No. 333-167015

    Registration No. 333-156538

    Registration No. 333-145291

    Registration No. 333-116697

     

     

     

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    Washington, D.C. 20549

     

     

    POST-EFFECTIVE AMENDMENT NO. 1 TO FORM S-8 REGISTRATION STATEMENT NO. 333-287395

    POST-EFFECTIVE AMENDMENT NO. 1 TO FORM S-8 REGISTRATION STATEMENT NO. 333-279772

    POST-EFFECTIVE AMENDMENT NO. 1 TO FORM S-8 REGISTRATION STATEMENT NO. 333-271947

    POST-EFFECTIVE AMENDMENT NO. 1 TO FORM S-8 REGISTRATION STATEMENT NO. 333-264880

    POST-EFFECTIVE AMENDMENT NO. 1 TO FORM S-8 REGISTRATION STATEMENT NO. 333-238926

    POST-EFFECTIVE AMENDMENT NO. 1 TO FORM S-8 REGISTRATION STATEMENT NO. 333-238925

    POST-EFFECTIVE AMENDMENT NO. 2 TO FORM S-8 REGISTRATION STATEMENT NO. 333-231366

    POST-EFFECTIVE AMENDMENT NO. 2 TO FORM S-8 REGISTRATION STATEMENT NO. 333-228290

    POST-EFFECTIVE AMENDMENT NO. 3 TO FORM S-8 REGISTRATION STATEMENT NO. 333-224924

    POST-EFFECTIVE AMENDMENT NO. 3 TO FORM S-8 REGISTRATION STATEMENT NO. 333-211643

    POST-EFFECTIVE AMENDMENT NO. 3 TO FORM S-8 REGISTRATION STATEMENT NO. 333-211642

    POST-EFFECTIVE AMENDMENT NO. 3 TO FORM S-8 REGISTRATION STATEMENT NO. 333-196263

    POST-EFFECTIVE AMENDMENT NO. 3 TO FORM S-8 REGISTRATION STATEMENT NO. 333-181710

    POST-EFFECTIVE AMENDMENT NO. 3 TO FORM S-8 REGISTRATION STATEMENT NO. 333-167015

    POST-EFFECTIVE AMENDMENT NO. 3 TO FORM S-8 REGISTRATION STATEMENT NO. 333-156538

    POST-EFFECTIVE AMENDMENT NO. 3 TO FORM S-8 REGISTRATION STATEMENT NO. 333-145291

    POST-EFFECTIVE AMENDMENT NO. 3 TO FORM S-8 REGISTRATION STATEMENT NO. 333-116697

     

    FORM S-8

    REGISTRATION STATEMENT

    UNDER

    THE SECURITIES ACT OF 1933

     

     

    ASSERTIO HOLDINGS, INC.

    (Exact name of registrant as specified in its charter)

     

     

    Delaware 85-0598378
    (State or other jurisdiction of
    incorporation or organization)

    (IRS employer

    identification number)

     

    100 South Saunders Road, Suite 300

    Lake Forest, Illinois 60045

    (Address of Principal Executive Offices, including Zip Code)

     

     

    Assertio Holdings, Inc. Amended and Restated 2014 Omnibus Incentive Plan

    Assertio Holdings, Inc. Inducement Award Program

    Assertio Therapeutics, Inc. Amended and Restated 2014 Omnibus Incentive Plan

    Assertio Therapeutics, Inc. Inducement Award Program

    Amended and Restated Assertio Holdings, Inc. 2004 Employee Stock Purchase Plan

    Zyla Life Sciences Amended and Restated 2019 Stock-Based Incentive Compensation Plan

    Depomed, Inc. Amended and Restated 2014 Omnibus Incentive Plan

    Depomed, Inc. 2014 Omnibus Incentive Plan

    Depomed, Inc. Amended and Restated 2004 Employee Stock Purchase Plan

    Depomed, Inc. 2004 Equity Incentive Plan

    Depomed, Inc. 2004 Employee Stock Purchase Plan

    (Full title of the Plans)

     

     

    Crystal Fisher

    Zydus Pharmaceuticals (USA) Inc., 73 Route 31 N., Pennington, New Jersey 08534

    Tel. (609) 730-1900

     

    (Name, Address and Telephone Number, including Area Code, of Agent for Service)

     

    Copies to:

     

    Ryan A. Murr

    Branden C. Berns

    Evan D’Amico

    Gibson, Dunn & Crutcher LLP

    One Embarcadero Center, Suite 2600

    San Francisco, California 94111-3715

    (415) 393-8373

     

    Krishna Veeraraghavan

    Chelsea Darnell

    Paul, Weiss, Rifkind, Wharton & Garrison LLP

    1285 Avenue of the Americas

    New York, New York 10019

    (212) 373-3000

     

     

    Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See definitions of “large accelerated filer, “accelerated filer,” “smaller reporting company,” and “emerging growth company” in Rule 12b-2 of the Exchange Act.

     

    Large accelerated filer ¨ Accelerated filer x
           
    Non-accelerated filer ¨ Smaller reporting company x
           
    Emerging growth company ¨    

     

    If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 7(a)(2)(B) of the Securities Act.  ¨

     

     

     

     

     

     

    EXPLANATORY NOTE

     

    DEREGISTRATION OF UNSOLD SECURITIES

     

    These Post-Effective Amendments (these “Post-Effective Amendments”) are being filed by Assertio Holdings, Inc., a Delaware corporation (the “Registrant”), to deregister all shares of the Registrant’s common stock, par value $0.0001 per share (the “Shares”), remaining unissued and unsold under the following Registration Statements on Form S-8 (each, a “Registration Statement”, and collectively, the “Registration Statements”) filed with the U.S. Securities and Exchange Commission (the “SEC”) by the Registrant or its predecessors, Assertio Therapeutics, Inc. and Depomed, Inc. (which Registration Statements were adopted by the Registrant pursuant to Rule 414 under the Securities Act of 1933, as amended).

     

      · Registration Statement on Form S-8 (No. 333-287395), filed with the SEC on May 19, 2025, pertaining to the registration of 8,200,000 Shares issuable under the Assertio Holdings, Inc. Amended and Restated 2014 Omnibus Incentive Plan (the “2014 Plan”).
      · Registration Statement on Form S-8 (No. 333-279772), filed with the SEC on May 29, 2024, pertaining to the registration of (i) 3,390,000 Shares issuable under the 2014 Plan and (ii) 3,000,000 Shares issuable pursuant to equity awards granted as inducement awards under the Assertio Holdings, Inc. Inducement Award Program.
      · Registration Statement on Form S-8 (No. 333-271947), filed with the SEC on May 15, 2023, pertaining to the registration of (i) 4,150,000 Shares issuable under the 2014 Plan, (ii) 58,572 Shares underlying outstanding stock options granted as inducement awards under the Assertio Therapeutics, Inc. Inducement Award Program (the “Inducement Program”) and (iii) 500,000 Shares issuable pursuant to equity awards to be granted as inducement awards under the Inducement Program.
      · Registration Statement on Form S-8 (No. 333-264880), filed with the SEC on May 12, 2022, pertaining to the registration of 5,400,000 Shares issuable under the 2014 Plan.
      · Registration Statement on Form S-8 (No. 333-238926), filed with the SEC on June 4, 2020, pertaining to the registration of (i) 13,000,000 Shares issuable under the 2014 Plan and (ii) 1,200,000 Shares issuable under the Amended and Restated Assertio Holdings, Inc. 2004 Employee Stock Purchase Plan.
      · Registration Statement on Form S-8 (No. 333-238925), filed with the SEC on June 4, 2020, pertaining to the registration of 4,985,875 Shares issuable under the Zyla Life Sciences Amended and Restated 2019 Stock-Based Incentive Compensation Plan.
      · Registration Statement on Form S-8 (No. 333-231366), filed with the SEC on May 10, 2019, pertaining to the registration of 3,650,000 Shares issuable under the Assertio Therapeutics, Inc. Amended and Restated 2014 Omnibus Incentive Plan.
      · Registration Statement on Form S-8 (No. 333-228290), filed with the SEC on November 9, 2018, pertaining to the registration of 1,047,900 Shares issuable pursuant to equity awards granted as inducement awards under the Inducement Program.
      · Registration Statement on Form S-8 (No. 333-224924), filed with the SEC on May 14, 2018, pertaining to the registration of 3,580,000 Shares issuable under the Depomed, Inc. Amended and Restated 2014 Omnibus Incentive Plan.
      · Registration Statement on Form S-8 (No. 333-211643), filed with the SEC on May 26, 2016, pertaining to the registration of 500,000 Shares issuable under the Depomed, Inc. Amended and Restated 2004 Employee Stock Purchase Plan.
      · Registration Statement on Form S-8 (No. 333-211642), filed with the SEC on May 26, 2016, pertaining to the registration of 2,400,000 Shares issuable under the Depomed, Inc. Amended and Restated 2014 Omnibus Incentive Plan.
      · Registration Statement on Form S-8 (No. 333-196263), filed with the SEC on May 23, 2014, pertaining to the registration of 6,150,000 Shares issuable under the Depomed, Inc. 2014 Omnibus Incentive Plan.
      · Registration Statement on Form S-8 (No. 333-181710), filed with the SEC on May 25, 2012, pertaining to the registration of (i) 5,200,000 Shares issuable under the Depomed, Inc. 2004 Equity Incentive Plan (the “2004 EIP”) and (ii) 1,000,000 Shares issuable under the Depomed, Inc. 2004 Employee Stock Purchase Plan (the “2004 ESPP”).
      · Registration Statement on Form S-8 (No. 333-167015), filed with the SEC on May 21, 2010, pertaining to the registration of (i) 2,500,000 Shares issuable under the 2004 EIP and (ii) 500,000 Shares issuable under the 2004 ESPP.

     

     

     

     

      · Registration Statement on Form S-8 (No. 333-156538), filed with the SEC on December 31, 2008, pertaining to the registration of 1,750,000 Shares issuable under the 2004 EIP.
      · Registration Statement on Form S-8 (No. 333-145291), filed with the SEC on August 9, 2007, pertaining to the registration of (i) 1,500,000 Shares issuable under the 2004 EIP and (ii) 500,000 Shares issuable under the 2004 ESPP.
      · Registration Statement on Form S-8 (No. 333-116697), filed with the SEC on June 21, 2004, pertaining to the registration of (i) 3,500,000 Shares issuable under the 2004 EIP and (ii) 500,000 Shares issuable under the 2004 ESPP.

     

    The Registrant is filing these Post-Effective Amendments to withdraw and remove from registration any unissued and unsold securities registered pursuant to the above-referenced Registration Statements.

     

    On May 13, 2026, the Registrant entered into an Agreement and Plan of Merger (the “Merger Agreement”) with Zydus Worldwide DMCC, a limited liability company incorporated under the laws of the United Arab Emirates (“Parent”), Zara Merger Sub Inc., a Delaware corporation and a wholly-owned subsidiary of Parent (“Purchaser”), and, solely for purposes of Section 9.20 thereof, Zydus Pharmaceuticals (USA) Inc., a New Jersey corporation. Pursuant to the Merger Agreement, on May 18, 2026, Purchaser commenced a tender offer (the “Offer”) to purchase all of the issued and outstanding Shares at a price of $23.50 per Share, payable in cash, without interest and subject to any applicable withholding of taxes. The Offer expired one minute after 11:59 p.m., Eastern Time, on June 15, 2026, and on June 16, 2026, Purchaser irrevocably accepted for payment all Shares validly tendered and not validly withdrawn pursuant to the Offer. On June 16, 2026, pursuant to the Merger Agreement and in accordance with Section 251(h) of the General Corporation Law of the State of Delaware, Purchaser merged with and into the Registrant (the “Merger”), with the Registrant continuing as the surviving corporation and a wholly-owned subsidiary of Parent.

     

    The foregoing description of the Offer, the Merger, the Merger Agreement and the transactions contemplated thereby does not purport to be complete and is subject to, and qualified in its entirety by, the Merger Agreement, which is attached as Exhibit 2.1 to the Registrant’s Current Report on Form 8-K filed with the SEC on May 13, 2026.

     

    As a result of the Merger, the Registrant has terminated all offerings of its securities pursuant to the Registration Statements. In accordance with an undertaking made by the Registrant in each of the Registration Statements to remove from registration, by means of a post-effective amendment, any of the securities that had been registered for issuance that remain unsold at the termination of the offerings, the Registrant hereby removes from registration all such securities registered under the Registration Statements that remain unsold as of the date hereof and terminates the effectiveness of the Registration Statements.

     

     

     

     

    SIGNATURE

     

    Pursuant to the requirements of the Securities Act of 1933, the Registrant certifies that it has reasonable grounds to believe that it meets all of the requirements for filing on Form S-8 and has duly caused these Post-Effective Amendments to the Registration Statements to be signed on its behalf by the undersigned, thereunto duly authorized, in Pennington, New Jersey, on June 16, 2026. No other person is required to sign these Post-Effective Amendments to the Registration Statements in reliance on Rule 478 of the Securities Act of 1933, as amended.

     

      ASSERTIO HOLDINGS, INC.
       
      /s/ Ravi Yadavar
     

    Name: Ravi Yadavar

    Title: Treasurer

     

     

     

     

    Get the next $ASRT alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $ASRT

    DatePrice TargetRatingAnalyst
    4/9/2026$18.00Buy → Neutral
    H.C. Wainwright
    7/26/2024$3.00Buy
    Maxim Group
    7/3/2024$4.00Buy
    H.C. Wainwright
    11/7/2022$7.00Buy
    Lake Street
    More analyst ratings

    $ASRT
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Director Mason Heather L bought $60,000 worth of shares (75,000 units at $0.80), increasing direct ownership by 35% to 287,650 units (SEC Form 4)

    4 - Assertio Holdings, Inc. (0001808665) (Issuer)

    11/19/24 9:02:18 AM ET
    $ASRT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    CEO O'Grady Brendan P. bought $9,950 worth of shares (11,706 units at $0.85) (SEC Form 4)

    4 - Assertio Holdings, Inc. (0001808665) (Issuer)

    11/15/24 2:43:25 PM ET
    $ASRT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Director Vacirca Jeff L bought $11,100 worth of shares (10,000 units at $1.11), increasing direct ownership by 7% to 151,159 units (SEC Form 4)

    4 - Assertio Holdings, Inc. (0001808665) (Issuer)

    6/12/24 6:00:09 PM ET
    $ASRT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ASRT
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Assertio Therapeutics downgraded by H.C. Wainwright with a new price target

    H.C. Wainwright downgraded Assertio Therapeutics from Buy to Neutral and set a new price target of $18.00

    4/9/26 8:30:00 AM ET
    $ASRT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Maxim Group initiated coverage on Assertio Therapeutics with a new price target

    Maxim Group initiated coverage of Assertio Therapeutics with a rating of Buy and set a new price target of $3.00

    7/26/24 7:49:44 AM ET
    $ASRT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    H.C. Wainwright initiated coverage on Assertio Therapeutics with a new price target

    H.C. Wainwright initiated coverage of Assertio Therapeutics with a rating of Buy and set a new price target of $4.00

    7/3/24 7:25:55 AM ET
    $ASRT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ASRT
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Director Mckee William closing all direct ownership in the company (SEC Form 4) (tax liability)

    4 - Assertio Holdings, Inc. (0001808665) (Issuer)

    6/16/26 6:38:06 PM ET
    $ASRT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    EVP, General Counsel Schlessinger Sam closing all direct ownership in the company (SEC Form 4) to satisfy withholding tax

    4 - Assertio Holdings, Inc. (0001808665) (Issuer)

    6/16/26 6:37:10 PM ET
    $ASRT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Director Kirk Sigurd closing all direct ownership in the company (SEC Form 4) (tax withholding)

    4 - Assertio Holdings, Inc. (0001808665) (Issuer)

    6/16/26 6:34:13 PM ET
    $ASRT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ASRT
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    $ASRT
    SEC Filings

    View All

    Assertio Announces Completion of Merger with Zydus Lifesciences and Fundamental Change and Make-Whole Fundamental Change Relating to its Outstanding 6.50% Convertible Senior Notes due 2027

    Assertio Holdings, Inc. (NASDAQ:ASRT) ("Assertio" or the "Company") today announced the successful completion of its previously announced merger (the "Merger") with Zydus Lifesciences Ltd. ("Zydus Lifesciences") pursuant to the terms of the Agreement and Plan of Merger, dated as of May 13, 2026 (the "Merger Agreement"), between, among others, the Company, Zydus Worldwide DMCC, a limited liability company incorporated under the laws of the United Arab Emirates and a wholly-owned subsidiary of Zydus Lifesciences ("Zydus") and Zara Merger Sub Inc., a Delaware corporation and wholly owned subsidiary of Zydus and Zydus Lifesciences ("Purchaser"). Assertio will continue to operate as a wholly-own

    6/16/26 4:30:00 PM ET
    $ASRT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Assertio to Be Acquired by Zydus Worldwide DMCC for $23.50 Per Share in Cash

    All-Cash Tender Offer of $23.50 per share or $166.4 Million Offer Represents 30.6% Premium to Original Agreement with Garda Therapeutics AND 75.8% Premium to Unaffected Price Assertio Holdings, Inc. (NASDAQ:ASRT) ("Assertio" or the "Company") today announced that, following an engagement process outlined under the revised merger agreement (the "Garda Merger Agreement") with Garda Therapeutics, Inc. ("Garda"), the Company's Board of Directors (the "Board") approved a definitive agreement with Zydus Worldwide DMCC, a subsidiary of Zydus Lifesciences Limited ("Zydus") to acquire all outstanding shares of Assertio common stock for $23.50 per share in cash, representing total consideration o

    5/13/26 8:00:00 AM ET
    $ASRT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Assertio and Garda Mutually Agree to Delay Launch of Tender Offer

    Assertio Holdings, Inc. ("Assertio" or the "Company") (NASDAQ:ASRT), today announced that it has reached a mutual agreement with Garda Therapeutics, Inc. ("Garda") to delay the launch of the previously announced tender offer to acquire all outstanding shares of Assertio to May 14, 2026. As previously announced on May 4, 2026, Assertio has entered into an amended and restated merger agreement (the "Garda Agreement") to be acquired by Garda for $21.80 per share in cash, or total cash consideration of $153.2 million. The Company expects to file a Schedule 14D-9 in connection with the tender offer on May 14, 2026. In addition, Assertio will delay the launch of the previously announced tender

    5/8/26 8:00:00 AM ET
    $ASRT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 25-NSE filed by Assertio Holdings Inc.

    25-NSE - Assertio Holdings, Inc. (0001808665) (Subject)

    7/7/26 10:46:54 AM ET
    $ASRT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 15-12G filed by Assertio Holdings Inc.

    15-12G - Assertio Holdings, Inc. (0001808665) (Filer)

    6/26/26 5:19:27 PM ET
    $ASRT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form EFFECT filed by Assertio Holdings Inc.

    EFFECT - Assertio Holdings, Inc. (0001808665) (Filer)

    6/18/26 12:15:03 AM ET
    $ASRT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ASRT
    Leadership Updates

    Live Leadership Updates

    View All

    Assertio Holdings, Inc. Appoints Mark Reisenauer to Its Board of Directors

    LAKE FOREST, Ill., Dec. 17, 2024 (GLOBE NEWSWIRE) -- Assertio Holdings, Inc. ("Assertio" or the "Company") (NASDAQ:ASRT), a pharmaceutical company with comprehensive commercial capabilities offering differentiated products to patients, announced today that Mark Reisenauer has been appointed as an independent director to the Company's Board of Directors. Mr. Reisenauer will serve as a member of the Compensation Committee. "Mark is a highly accomplished commercial leader in complex, competitive therapeutic areas who also brings extensive oncology and hematology product experience to our board," said Heather Mason, Chair of Assertio. "His successful new product and indication launches have b

    12/17/24 8:30:00 AM ET
    $ASRT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Assertio Holdings, Inc. Appoints Paul Schwichtenberg to New CTO Role, Mary Pietryga as CCO

    LAKE FOREST, Ill., Dec. 12, 2024 (GLOBE NEWSWIRE) -- Assertio Holdings, Inc. ("Assertio" or the "Company") (NASDAQ:ASRT), a pharmaceutical company with comprehensive commercial capabilities offering differentiated products to patients, announced today the creation of a new Transformation Office and the appointment of Paul Schwichtenberg as Chief Transformation Officer (CTO). Mr. Schwichtenberg currently serves as the company's Chief Commercial Officer and was previously CFO. "As CTO, Paul will be future looking, working closely with me, to identify synergies, innovative strategies, and new revenue streams to best position the company for future growth," said Brendan O'Grady, Chief Executi

    12/12/24 8:00:00 AM ET
    $ASRT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Beam Therapeutics Announces Appointment of Sravan Emany as Chief Financial Officer

    CAMBRIDGE, Mass., Dec. 06, 2024 (GLOBE NEWSWIRE) -- Beam Therapeutics Inc. (NASDAQ:BEAM), a biotechnology company developing precision genetic medicines through base editing, today announced the appointment of Sravan K. Emany as chief financial officer (CFO), effective December 19, 2024. Mr. Emany brings to Beam a breadth of global operational, commercial and financial experience with multinational public corporations and financial institutions. He most recently served as CFO and chief operating officer at Ironwood Pharmaceuticals, Inc. "Beam has built a strong financial position to advance our portfolio of genetic medicines, and Sravan has an exceptional background to lead our capital fo

    12/6/24 7:00:00 AM ET
    $ASRT
    $BEAM
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Biotechnology: Biological Products (No Diagnostic Substances)

    $ASRT
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13G/A filed by Assertio Holdings Inc.

    SC 13G/A - Assertio Holdings, Inc. (0001808665) (Subject)

    11/14/24 3:52:50 PM ET
    $ASRT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SC 13G/A filed by Assertio Holdings Inc.

    SC 13G/A - Assertio Holdings, Inc. (0001808665) (Subject)

    11/12/24 1:34:28 PM ET
    $ASRT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SC 13G/A filed by Assertio Holdings Inc.

    SC 13G/A - Assertio Holdings, Inc. (0001808665) (Subject)

    11/4/24 11:29:13 AM ET
    $ASRT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ASRT
    Financials

    Live finance-specific insights

    View All

    Assertio Announces Amended and Restated Merger Agreement with Garda Therapeutics

    Increased All-Cash Tender Offer Price of $21.80 per share – or $153.2 Million New Tender Offer Price Represents 21.1% Premium to Prior Offer Assertio Holdings, Inc. (NASDAQ:ASRT) ("Assertio" or the "Company") today announced that, on May 1, 2026, Assertio and Garda Therapeutics ("Garda") entered into an Amended and Restated Agreement and Plan of Merger (the "Merger Agreement"), pursuant to which Garda has increased its offer to acquire all outstanding shares of Assertio to $21.80 per share in cash with no contingent value right. The increased offer represents a 21.1% premium to Garda's original offer on April 8, 2026, and a 63.1% premium to the Company's unaffected stock price on Marc

    5/4/26 8:00:00 AM ET
    $ASRT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Assertio Holdings, Inc. to Report Fourth Quarter and Full Year 2025 Financial Results on March 16, 2026

    Assertio Holdings, Inc. ("Assertio") (NASDAQ:ASRT) today announced that it will release fourth quarter and full year 2025 financial results on Monday, March 16, 2026, after the market close. Following the release of its financial results, Assertio's management will host a live webcast of the earnings conference call at 4:30 p.m. Eastern Time. To access the live webcast, conference call information, and other materials, please visit Assertio's investor relations website at http://investor.assertiotx.com/overview/default.aspx. Please connect at least 10 minutes prior to the live webcast to ensure adequate time for any software download that may be needed to access the webcast. For those wis

    3/3/26 4:30:00 PM ET
    $ASRT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Assertio Announces Leadership Transition

    Appoints Industry Veteran and Current Director Mark L. Reisenauer as CEO, Effective Immediately Company Will Report Third Quarter Results on November 10, 2025 and Expects to Update Guidance Within the Current Range at That Time LAKE FOREST, Ill., Oct. 28, 2025 (GLOBE NEWSWIRE) -- Assertio Holdings, Inc. ("Assertio" or the "Company") (NASDAQ:ASRT), today announced that its Board of Directors (the "Board") has appointed director Mark L. Reisenauer as the Company's Chief Executive Officer ("CEO"), effective immediately. As part of this transition, current CEO Brendan P. O'Grady will be departing the Company. Heather L. Mason, Chair of the Board of Directors, stated, "After significant del

    10/28/25 9:15:00 AM ET
    $ASRT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ASRT
    Insider purchases explained

    Analytical look into recent insider purchases

    View All

    Insider Analysis: Purchase at Assertio Holdings Inc. on Jun 6

    Recent insider transactions at Assertio Holdings Inc. have brought attention to the company's stock activity. On June 6, 2024, Mason Heather L purchased $24,250 worth of shares, acquiring 25,000 units at $0.97 per share. This transaction increased Mason Heather L's direct ownership by 13% to 212,650 units, as reported in the SEC Form 4. Several other notable insider transactions have taken place at Assertio Holdings Inc. leading up to this purchase. Patel Ajay, Schwichtenberg Paul, and Schlessinger Sam all converted options into shares and covered exercise/tax liability by utilizing their shares. These transactions resulted in ownership increases of 16%, 20%, and 21%, respectively. Addition

    6/10/24 1:20:50 AM ET
    $ASRT
    Biotechnology: Pharmaceutical Preparations
    Health Care